Introduction
Renal function measurement is often focused on the GFR and, to a lesser extent, on renal blood flow (1) . The gold standard for measuring GFR is inulin clearance (2) . However, nuclear medicine studies have replaced inulin clearance because of convenience and absence of urine collection. In Europe, 51 Cr-EDTA is the most widely used method for the determination of GFR (3), whereas in North America, the 99 Tc-diethylenetriamine pentaacetic acid renal scan enjoys the most widespread utilization (3) (4) (5) . Although less demanding than inulin clearance studies, nuclear GFR studies are still cumbersome, invasive, and involve radiation. Endogenous markers for estimated GFR (eGFR), such as serum creatinine and more recently cystatin C (CysC), are hampered by diagnostic imprecision (6) . Recently beta trace protein (BTP) has been introduced as a surrogate marker for GFR measurement (7) .
Creatinine (molecular weight ϭ 113 D, neutrally charged) is the metabolic product of creatine and phosphocreatine found in muscle; therefore, it reflects muscle mass (8, 9) . Given the large variability of muscle mass, there is substantial interpatient variability of serum creatinine concentration (10) because of its high water solubility (11) .
Serum CysC has been shown to be an excellent marker for GFR (6, 12, 13) . It is a small-molecularweight protein (molecular weight ϭ 13 kD, positive charge with isoelectric point of 9.3) that was initially known as ␥-trace protein and its amino acid sequence was determined in 1981 (14, 15) . This protein is produced at a very constant rate and is affected by only a few conditions, such as uncontrolled hyperthyroidism (16) .
BTP (molecular weight ϭ 23 to 29 kD, mildly negatively charged with isoelectric point of 5.8 to 6.7, also known as prostaglandin D synthase) has been traditionally used as a marker of cerebrospinal fluid leakage (17, 18) . It is expressed in all tissues except the ovaries (19) . Preliminary studies have confirmed a good correlation between serum BTP levels and GFR measurement by inulin clearance and nuclear medicine techniques (5, 20) .
Hyperfiltration is considered an abnormal increase in the GFR (21, 22) . However, this definition ignores the fact that hyperfiltration can take place in a single nephron even with globally decreased GFR. Other sources have defined hyperfiltration as the result of an increase in the glomerular capillary pressure (23, 24) . The filtration fraction (FF) is the ratio of GFR and effective renal plasma flow (ERPF) (24) . A normal FF is 18.7 Ϯ 3.2% in healthy young adults between the ages of 20 and 30 years (25) . Hyperfiltration should be considered if the FF is above the reference interval.
We were interested in whether hyperfiltration affects the diagnostic accuracy of commonly used eGFR measurements using creatinine, CysC, and BTP in a pediatric population. The precision between the surrogate markers and the eGFR is reduced at higher GFR. One possible explanation for this phenomenon may be that some patients hyperfilter and others do not.
Patients and Methods

Patients
The study received full approval of the local ethics boards and was in accordance with the ethical standards of the Helsinki declaration of 1975 (revised in 1983) (5 
Materials and Methods
The methods for the simultaneous measurement of GFR and ERPF using 51 Cr-EDTA renal scan with concomitant determination of the 131 I-hippurate clearance have been described elsewhere (25) Schwartz. We validated these revised constants for the Schwartz formula in our patient cohort. For adolescent boys, the estimated constant was 49.4 Ϯ 10.5, not significantly different from 48 (P ϭ 0.3271, one-sample t test). For the nonadolescent male patients, the constant was 40.3 Ϯ 7.7, again not significantly different from 38. We therefore used the constants of 38 and 48. The formula reads
The methods for the determination of CysC (Siemens Diagnostics GmbH) and BTP (Siemens Diagnostics) were described in the previous study (5) . CysC eGFR was calculated using the Filler formula (27) . For the BTP eGFR, we used a recently published and validated formula by Benlamri et al. (28) .
We calculated the error between the measured GFR and the eGFR for creatinine using Schwartz, CysC, and BTP using (eGFR Parameter Ϫ measured GFR)/measured GFR.
Statistical Analyses
All statistical analyses were performed using GraphPad Prism Software for Science Version 4.0c (San Diego, CA). Standard regression and correlation analyses were applied. Normal distribution was assessed using the Shapiro-Wilk test.
Agreement between methods was tested using the Bland-Altman plot method (29) . The Bland-Altman plot is a statistical method used to compare two measurement techniques. In this graphical method, the differences (or alternatively the ratios) between the two techniques are plotted against the averages of the two techniques. Horizontal lines are drawn at the mean difference, and at the mean difference Ϯ 1.96 times the SD of the differences. If the differences within the mean Ϯ 1.96 SD are not clinically important, the two methods may be used interchangeably. SD of the differences between the two assay methods is used to calculate the limits of agreement, computed as the mean bias Ϯ 1.96 times its SD. The bias is computed as the value determined by one method minus the value determined by the other method. If one method is sometimes higher, and sometimes the other method is higher, the average of the differences will be close to zero. If it is not close to zero, this indicates that the two assay methods are producing different results. Correlation analysis was performed using appropriate parametric (in case of normal distribution) or nonparametric tests (Spearman rank). In the case of non-normal distribution, data are given as a median (25th percentile, 75th percentile). The percentiles in brackets are also known as the interquartile range (IQR). P Ͻ 0.05 was considered statistically significant.
Results
The 127 children had a median age of 11.9 (IQR 8. Table 1 .
Bland-Altman analysis revealed a bias of 10.8% Ϯ 21.2%, with a 95% limit of agreement from Ϫ0.8% to 52.4% between the Schwartz formula eGFR and the measured GFR. For CysC, the bias was Ϫ9.6% Ϯ 21.6% with a 95% limit of agreement from Ϫ52.0% to 32.7%, and for BTP the bias was 1.4 Ϯ 28.3 with a 95% limit of agreement from Ϫ54.0% to 56.8% ( Table 2) .
The median (IQR) relative error (eGFR Ϫ GFR/ GFR) for the Schwartz formula was ϩ12 (IQR Ϫ4, ϩ24)%, whereas the median error for CysC eGFR was Ϫ9 (IQR Ϫ21, ϩ6)%, and for BTP eGFR was ϩ5 (IQR Ϫ16, ϩ25)% (Table 3) .
There was no correlation between the FF and the error for CysC eGFR and BTP eGFR, whereas there was a significant negative correlation between the error for the Schwartz eGFR and the FF (Figure 1 ). Furthermore, a significant negative correlation existed between FF and GFR, Schwartz GFR, CysC eGFR, and BTP eGFR. Clinically, this suggests that most patients with a lower GFR hyperfilter, whereas only some hyperfilter with normal GFR. Table 4 summarizes the correlation analysis (Spearman rank). There was no significant correlation between the error for the CysC eGFR and BTP eGFR and the FF. On the other hand, a significant negative correlation existed between FF and GFR, Schwartz GFR, CysC eGFR, and BTP eGFR.
Discussion
The main finding of the study was that creatininebased eGFR was influenced by the FF, whereas the accuracy of the eGFR from the Filler equation using serum CysC and the Belamri equation using serum BTP was unaffected. In fact, there was a significant negative correlation between error of eGFR calculated from the Schwartz formula and the measured GFR and the FF. To the best of our knowledge, this is the first study that demonstrates that the error between Schwartz formula eGFR and measured GFR is altered by hyperfiltration. By contrast, eGFR based on lowmolecular-weight proteins was not altered by hyperfiltration. This finding is novel and has significant implications. Previous studies have focused on the errors in eGFR from various surrogate markers and their respective formulas to the nuclear GFR studies (30 -32) . Better agreement was consistently found in the low GFR range, whereas the precision between measured GFR and surrogate marker eGFR worsened with normal and high GFR values (24, 30) . It was therefore logical to assess the effect of hyperfiltration on the diagnostic performance of surrogate eGFR markers. Previous studies did not include ERPF or FF.
What does this mean? It appears that a small-molecular-weight soluble substance can be affected by hyperfiltration, which weakens its diagnostic performance as a GFR marker, whereas low-molecularweight proteins are unaffected. This would render serum creatinine a less accurate marker for eGFR in the presence of hyperfiltration. Because GFR may remain constant in the early stages of chronic kidney disease whereas the nephron endowment deteriorates secondary to a renal disease, patients with a normal GFR may or may not be hyperfiltrating. In advanced chronic kidney disease, all remaining nephrons hyperfilter (33) . It is therefore conceivable that the degree of hyperfiltration may serve as the main explanation for the reduced precision of any surrogate GFR marker in the normal and high GFR range. Admittedly, the correlation was only 0.24, which was significant, but not very impressive. The study was not designed to discover a strong correlation between the error of a creatinine-based eGFR formula and the FF; rather, it was designed to test the hypothesis whether some of the variance of the scatter can be explained by the degree of hyperfiltration. The clinical significance of our findings lies in the fact that hyperfiltration can indeed explain some of the imprecision of creatininebased eGFR, and patients early in the course of diabetic nephropathy and IgA nephropathy may especially have significant hyperfiltration. In the low GFR range, the phenomenon becomes less important, but our data suggest that creatinine handling may be altered by the FF to a degree that it renders the marker less favorable when compared with the low-molecular-weight eGFR markers.
Of course, the question arises as to why the small molecule creatinine is handled differently than the small-molecular-weight proteins CysC and BTP. All surrogate eGFR markers have different charges and isoelectric points. Because CysC and BTP are handled identically, electric charge is unlikely to explain the negative correlation between the error in eGFR for creatinine in the measurement of the FF. One possible explanation for this increase in error in creatininebased eGFR using the Schwartz formula is that creat- inine is also secreted by the renal tubule along with the excretion from glomerular filtration, whereas there is minimal or no tubular reabsorption of creatinine (34) . CysC and BTP are exclusively eliminated through glomerular filtration. Therefore, with low FF, there is more blood flow in the efferent arteriole and subsequently more creatinine available in the peritubular capillaries for tubular secretion. This may lead to an increase of tubular secretion at lower FF, thereby creating an overestimation in the eGFR. It should be noted that the difference between the 25th and 75th percentile (i.e., IQR, a measure of precision) was inferior for BTP, suggesting that of the two low-molecular-weight proteins, CysC should be preferred. When the FF is increased, there is a decrease in efferent blood flow with a subsequent decrease of creatinine available for tubular secretion. Therefore, the eGFR from the creatinine-based formula correlates better with measured GFR at higher FF. The proposed differential handling of creatinine with lower and higher FF is demonstrated in Figure 2 . Because tubular secretion does not modify CysC and BTP concentrations, the FF is unaffected by the error between the eGFR errors for CysC and the BTP-based formulas.
Our study has limitations. The first limitation is related to the nuclear medicine methods chosen to determine GFR and ERPF. No separate gold standard such as inulin clearance and para-aminohippuric acid (PAH) clearance were used to evaluate the accuracy of the nuclear medicine methods. Nuclear medicine methods are known to be imperfect measures of GFR and ERPF. Inulin and PAH clearance studies are no longer performed in most tertiary centers. However, the methods were validated and performed as described in reference 25 as the standard of care. Although earlier studies comparing inulin clearance and 51 Cr-EDTA clearance mostly reported correlations upon introduction of the nuclear medicine methods, a recent study from Medeiros et al. used appropriate testing for agreement with Bland-Altman analysis for an identical method to ours and revealed narrow limits of agreement and a difference (bias) of 2.8 and 2.7 ml/min, respectively. They concluded that 51 Cr-EDTA clearance was a reliable method to measure GFR compared with inulin clearance (35) . We are unaware of any modern studies using Bland-Altman analysis to study agreement between 131 I-hippurate clearance with PAH clearance; however, a study from 1980 demonstrated identical results with PAH clearance and slightly better performance of the 131 I-hippurate clearance that we used in our study when compared with PAH clearance (36) . Furthermore, this study was conducted in a pediatric population and it is unclear whether these findings can be generalized to all ages. In children, eGFR is calculated using the Schwartz formula that is based on creatinine and patient height. Adult eGFR calculations based on serum creatinine, such as the Modification of Diet in Renal Disease study equation and the CockcroftGault equation, require additional information such as age, weight, gender, and ethnicity. In children, these formulas cannot be used (37) . Before the findings of this study can be generalized, the increased eGFR errors that occur at lower FF will need to be confirmed in adult populations using adult eGFR equations that are based on serum creatinine.
The eGFR errors using the Schwartz formula change with the state of FF. It is impractical to measure FF in every patient. FF can only be measured if GFR and ERPF are determined simultaneously. In Canada, 131 I or 121 I-PAH are not commercially available. Furthermore, for a simultaneous nuclear medicine method, two different isotopes with ␥ and ␤ radiation are required, which is impractical in North America because 51 Cr-EDTA is not commercially available (38) . Although we have a general rule of thumb that the tubular secretion for creatinine is approximately 10% of the total excretion (34), this may not be applicable for different degrees of hyper- filtration. The creatinine-based eGFR formulas may be unpredictable in terms of the eGFR errors. Other limitations include a relatively low sample size of 127 patients and a small proportion of patients with low GFR. Our study casts significant doubts on the accuracy of serum creatinine in patients with a variable degree of hyperfiltration. Early in the course of disease, hyperfiltration may or may not be operant. In the case of a GFR Ͼ150 ml/min per 1.73 m 2 , hyperfiltration can be assumed, but in the case of normal GFR, hyperfiltration may or may not occur. Our study suggests that a surrogate marker for eGFR should be based on a low-molecular-weight protein rather than on serum creatinine.
The question of the clinical applicability of these findings remains to be established. Short of performing a proper inulin and PAH clearance study, FF is not easily measurable. Clinically, we assume hyperfiltration whenever the GFR is high. Our study also suggests that all patients with a low GFR hyperfilter. The importance of this study lies less in the clinical applicability of the effect of hyperfiltration on creatinine excretion, but more points to an important factor that explains some of the scatter when using surrogate markers for the estimation of eGFR. The study also suggests that CysC is less affected by hyperfiltration than creatinine.
In conclusion, this study showed that the creatinine-based Schwartz formula is influenced by FF. The errors of eGFR negatively correlate with FF. Only the eGFRs based on low-molecular-weight proteins (Filler equation using CysC and the Belarmi equation using BTP) are unaffected at different levels of FF. Further studies are required to test the result in adult populations with other creatinine-based formulas.
